Ofer Goldberg - Clal Biotechnology Insider

Clal Biotechnology Industries Ltd -- Israel Stock  

ILS 327.00  323.72  9,870%


Mr. Ofer Goldberg serves as Vice President at Clal Biotechnology Industries Ltd. since September 1, 2003. Previously, Mr. Goldberg served as Director for BioCancell Therapeutics Inc from May 17, 2007 to October 21, 2009
Age: 42  VP Since 2003      
972 3 612 1616  http://www.cbi.co.il
Goldberg has a Bachelors degree in Mathematics and Physics from The Hebrew University of Jerusalem and a Masters degree in Finance and Economics from the TelAviv University.

Management Efficiency

The company has return on total asset (ROA) of (4.67) % which means that it has lost $4.67 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (26.55) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 77.26 M in total debt with debt to equity ratio (D/E) of 9.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Clal Biotechnology Industries Ltd has Current Ratio of 4.64 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Found 3 records

VP Since

Eyal KamilBezeq The Israel Telecommunicat
Yitzhak MosheOil Refineries Ltd
Yaron NimrodOil Refineries Ltd

Entity Summary

Clal Biotechnology Industries Ltd. is a private equity and VC firm specializing in development stage, preclinical; incubation, seed, startup, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. Clal Biotechnology Industries Ltd (CBI) is traded on Tel Aviv Stock Exchange in Israel. It is located in Tel Aviv, and employs 14 people.

Did you try this?

Run Technical Analysis Now

Technical Analysis

Check basic technical indicators and analysis based on most latest market data
Hide  View All  NextLaunch Technical Analysis
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Clal Biotechnology Industries Ltd to your portfolio

Top Management

Clal Biotechnology I Leadership Team
Ofer Goldberg, VP
Sigalia Heifetz, Director
Shmuel Rubinstein, Director
Tomer Babai, Director
Dafna Gruber, Director
Aharon Schwartz, Director
Gavriel Barabash, Director, Ph.D
Isaac Kohlberg, Director, MBA
Nofar Malovani, Director
Assaf Segal, CFO, MBA
Ofer Gonen, President
Avraham Fischer, Chairman
Yuval Yanai, Director
Julian Adams, President
Orit Lidor, VP

Stock Performance

Clal Biotechnology Performance Indicators